Literature DB >> 24040869

Standard and emerging treatment options for diabetic neuropathy.

Nicholas Tentolouris, Kleopatra Alexiadou, Konstantinos Makrilakis, Stavros Liatis, Edward Jude, Andrew J Boulton1.   

Abstract

Diabetic neuropathy is a common complication of diabetes mellitus affecting 30-50% of patients and is a major cause for increased costs, morbidity and mortality. Strict diabetes control prevents this complication and may restore neurologic deficits in the early stages. Several efforts have been undertaken to alter the natural history of this complication, including the use of aldose reductase and protein kinase-C inhibitors, as well as antioxidants. Available data so far do not support the use of aldose reductase inhibitors due to safety issues and efficacy. Protein kinase-C inhibitors have provided encouraging initial results but their development has been halted. Antioxidants, like a-lipoic acid, improve some neurological deficits and painful symptoms. There are effective and safe medications such as anticonvulsants, antidepressants and opioids for the management of patients with painful symptoms. In this revew we present standard and emerging treatment modalities for the etiologic and symptomatic treatment of diabetic neuropathy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24040869     DOI: 10.2174/13816128113196660682

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  4 in total

Review 1.  Schwann cell interactions with axons and microvessels in diabetic neuropathy.

Authors:  Nádia P Gonçalves; Christian B Vægter; Henning Andersen; Leif Østergaard; Nigel A Calcutt; Troels S Jensen
Journal:  Nat Rev Neurol       Date:  2017-01-30       Impact factor: 42.937

2.  Use of an alpha lipoic, methylsulfonylmethane and bromelain dietary supplement (Opera®) for chemotherapy-induced peripheral neuropathy management, a prospective study.

Authors:  Isacco Desideri; Giulio Francolini; Carlotta Becherini; Francesca Terziani; Camilla Delli Paoli; Emanuela Olmetto; Mauro Loi; Marco Perna; Icro Meattini; Vieri Scotti; Daniela Greto; Pierluigi Bonomo; Susanna Sulprizio; Lorenzo Livi
Journal:  Med Oncol       Date:  2017-02-15       Impact factor: 3.064

3.  Diabetic neuropathy: are we still barking up the wrong tree and is change finally in sight?

Authors:  David V Coppini
Journal:  Diabetologia       Date:  2020-07-17       Impact factor: 10.122

4.  Prevalence, discomfort and self-relief behaviours of painful diabetic neuropathy in Taiwan: a cross-sectional study.

Authors:  Sui-Whi Jane; Ming-Shyan Lin; Wen-Nan Chiu; Randal D Beaton; Mei-Yen Chen
Journal:  BMJ Open       Date:  2016-10-03       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.